Abstract |
Late-onset GM2 gangliosidosis is composed of two related, autosomal recessive, neurodegenerative diseases, both resulting from deficiency of lysosomal, heterodimeric beta-hexosaminidase A ( Hex A, alphabeta). Pharmacological chaperones (PC) are small molecules that can stabilize the conformation of a mutant protein, allowing it to pass the quality control system of the endoplasmic reticulum. To date all successful PCs have also been competitive inhibitors. Screening for Hex A inhibitors in a library of 1040 Food Drug Administration-approved compounds identified pyrimethamine (PYR (2,4-diamino 5-(4-chlorophenyl)-6-ethylpyrimidine)) as the most potent inhibitor. Cell lines from 10 late-onset Tay-Sachs (11 alpha-mutations, 2 novel) and 7 Sandhoff (9 beta-mutations, 4 novel) disease patients, were cultured with PYR at concentrations corresponding to therapeutic doses. Cells carrying the most common late-onset mutation, alphaG269S, showed significant increases in residual Hex A activity, as did all 7 of the beta-mutants tested. Cells responding to PC treatment included those carrying mutants resulting in reduced Hex heat stability and partial splice junction mutations of the inherently less stable alpha-subunit. PYR, which binds to the active site in domain II, was able to function as PC even to domain I beta-mutants. We concluded that PYR functions as a mutation-specific PC, variably enhancing residual lysosomal Hex A levels in late-onset GM2 gangliosidosis patient cells.
|
Authors | Gustavo H B Maegawa, Michael Tropak, Justin Buttner, Tracy Stockley, Fernando Kok, Joe T R Clarke, Don J Mahuran |
Journal | The Journal of biological chemistry
(J Biol Chem)
Vol. 282
Issue 12
Pg. 9150-61
(Mar 23 2007)
ISSN: 0021-9258 [Print] United States |
PMID | 17237499
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Enzyme Inhibitors
- Folic Acid Antagonists
- Molecular Chaperones
- Hexosaminidase A
- beta-N-Acetylhexosaminidases
- Pyrimethamine
|
Topics |
- Dimerization
- Dose-Response Relationship, Drug
- Enzyme Inhibitors
(pharmacology)
- Fibroblasts
(metabolism)
- Folic Acid Antagonists
(pharmacology)
- Gangliosidoses, GM2
(drug therapy, metabolism)
- Hexosaminidase A
- Humans
- Lysosomes
(metabolism)
- Models, Molecular
- Molecular Chaperones
- Mutation
- Mutation, Missense
- Protein Folding
- Pyrimethamine
(pharmacology)
- beta-N-Acetylhexosaminidases
(antagonists & inhibitors)
|